Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.59 |
| ▸ | MME | P08473 | 2/20 | 0.59 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.56 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5603448 | 1.00 | ACE (0.59) | ACEMMEMMEL1NAALAD2 | |
| SCHEMBL391211 | 1.00 | ACE (0.59) | ACEMMEMMEL1NAALAD2 | |
| SCHEMBL7380315 | 0.95 | MMEL1 (0.64) | ACEMMEMMEL1 | |
| SCHEMBL7385743 | 0.95 | MMEL1 (0.64) | ACEMMEMMEL1 | |
| SCHEMBL11296564 | 0.92 | ATM (0.52) | ACEMMENAALAD2 | |
| SCHEMBL7385019 | 0.91 | MME (0.64) | ACEMMEMMEL1NAALAD2 | |
| Water SCHEMBL10949495 | 0.90 | MME (0.62) | ACEMMEMMEL1NAALAD2 | |
| SCHEMBL9068701 | 0.89 | FOLH1 (0.52) | NAALAD2 | |
| SCHEMBL10944494 | 0.87 | ACE (0.50) | ACEMMEMMEL1 | |
| SCHEMBL7373739 | 0.86 | MME (0.48) | ACEMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 272 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0605589-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NATRIURETIC PEPTIDES OR NEUTRAL ENDOPEPTIDASE INHIBITORS FOR TREATING OR PREVENTING MYOINTIMAL PROLIFERATION | SCHERING CORPORATION (US) | 1994-07-13 | — | — | EP | claimed |
| WO-1993010773-A1 | USE OF NEUTRAL ENDOPEPTIDASE INHIBITORS IN THE TREATMENT OF LEFT VENTRICULAR HYPERTROPHY | SCHERING-PLOUGH S.P.A. (IT) | 1993-06-10 | — | — | WO | claimed |
| WO-1993005809-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NATRIURETIC PEPTIDES OR NEUTRAL ENDOPEPTIDASE INHIBITORS FOR TREATING OR PREVENTING MYOINTIMAL PROLIFERATION | SCHERING CORPORATION (US) | 1993-04-01 | — | — | WO | claimed |
| EP-0533084-A1 | Pharmaceutical compositions comprising natriuretic peptides or neutral endopeptidase inhibitors for treating and preventing myointimal proliferation | SCHERING CORPORATION (US) | 1993-03-24 | — | — | EP | claimed |
| WO-1992018159-A1 | USE OF NEUTRAL ENDOPEPTIDASE INHIBITORS IN THE TREATMENT OF NEPHROTOXICITY | SCHERING CORPORATION (US) | 1992-10-29 | — | — | WO | claimed |
| EP-0509442-A1 | Use of neutral endopeptidase inhibitors in the treatment of nephrotoxicity | SCHERING CORPORATION (US) | 1992-10-21 | — | — | EP | claimed |
| EP-0415693-A1 | Composition and method for selective enhancement of opiate activity and reduction of opiate tolerance and dependence | ARIZONA TECHNOLOGY DEVELOPMENT CORPORATION (US) | 1991-03-06 | — | — | EP | claimed |
| US-4749688-A | Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension | SCHERING CORPORATION (US) | 1988-06-07 | — | — | US | claimed |
| EP-0103077-B1 | SUBSTITUTED DIPEPTIDES, METHODS FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, METHOD FOR MAKING SUCH PHARMACEUTICAL COMPOSITIONS | SCHERING CORPORATION (US) | 1988-05-18 | — | — | EP | claimed |
| US-4610816-A | ANALGESICS | SCHERING CORPORATION (US) | 1986-09-09 | — | — | US | claimed |
| EP-0103077-A2 | Substituted dipeptides, methods for their production, pharmaceutical compositions containing them, method for making such pharmaceutical compositions | SCHERING CORPORATION (US) | 1984-03-21 | — | — | EP | claimed |
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | disclosed |
| US-11919888-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-03-05 | — | — | US | disclosed |
| US-11851443-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-05 | — | — | US | disclosed |
| EP-0254032-A2 | Neutral metalloendopeptidase inhibitors in the treatment of hypertension | SCHERING CORPORATION (US) | 1988-01-27 | — | — | EP | disclosed |
| US-4721726-A | ANALGESICS | SCHERING CORPORATION (US) | 1988-01-26 | — | — | US | disclosed |
| US-4610816-A | ANALGESICS | SCHERING CORPORATION (US) | 1986-09-09 | — | — | US | disclosed |
| EP-0054862-B1 | SUBSTITUTED DIPEPTIDES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE INHIBITION OF ENKEPHALINASE | SCHERING CORPORATION (US) | 1985-11-27 | — | — | EP | disclosed |
| EP-0103077-A2 | Substituted dipeptides, methods for their production, pharmaceutical compositions containing them, method for making such pharmaceutical compositions | SCHERING CORPORATION (US) | 1984-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | ACE 3/4885MME 1/4885MMEL1 240/4885 |
| US-11851443-B2 | Neprilysin inhibitors | MME, REN, ACE | ACE 3/4885MME 1/4885MMEL1 237/4885 |
| US-12016835-B2 | Neprilysin inhibitors | MME, REN, ACE | ACE 3/4885MME 1/4885MMEL1 213/4885 |
| US-11919888-B2 | Neprilysin inhibitors | MME, REN, ACE | ACE 3/4885MME 1/4885MMEL1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.